US 11,883,601 B2
Nasal cannula
Robert M. Landis, Mountainside, NJ (US); Charles A. Lewis, Carrabelle, FL (US); and Louis Javier Collazo, Lauderdale by the Sea, FL (US)
Assigned to ResMed Pty Ltd
Filed by ResMed Pty Ltd, Bella Vista (AU)
Filed on Jun. 5, 2020, as Appl. No. 16/894,453.
Application 16/894,453 is a continuation of application No. 14/266,659, filed on Apr. 30, 2014, granted, now 10,675,427.
Application 14/266,659 is a continuation of application No. 11/520,490, filed on Sep. 12, 2006, abandoned.
Claims priority of provisional application 60/716,776, filed on Sep. 12, 2005.
Prior Publication US 2020/0297961 A1, Sep. 24, 2020
Int. Cl. A61M 16/06 (2006.01); A61M 16/00 (2006.01); A61M 16/10 (2006.01)
CPC A61M 16/0672 (2014.02) [A61M 16/0003 (2014.02); A61M 16/0666 (2013.01); A61M 16/0677 (2014.02); A61M 2016/1025 (2013.01); A61M 2205/18 (2013.01); A61M 2205/3331 (2013.01); A61M 2205/3368 (2013.01); A61M 2205/3379 (2013.01); A61M 2230/42 (2013.01); A61M 2230/432 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A nasal cannula comprising:
a base portion defining a first therapeutic gas passageway;
a nasal insert disposed adjacent said base portion and defining a second therapeutic gas passageway, said first therapeutic gas passageway being in gaseous communication with said second therapeutic gas passageway;
at least one sensor for measuring the properties of gas adjacent said nasal insert, wherein the at least one sensor is disposed adjacent to or within said nasal insert;
an outlet formed in said base portion; and
an electrical wire that extends from the at least one sensor through said second therapeutic gas passageway and said outlet.